|Lung SqCC Stained with p40 (M)|
Mouse monoclonal anti-p40 [BC28] has demonstrated similar sensitivity and specificity as the rabbit polyclonal p40, staining 97% (65/67) of cases of lung squamous cell carcinoma (SqCC) and 0% (0/71) cases of lung adenocarcinoma (ADC), in an in-house study.
“Biocare Medical continually strives to improve the diagnostic tools available to pathologists,” says David Tacha, PhD, chief scientific officer, Biocare Medical. “With the introduction of the p40 monoclonal antibody, we hope to further enhance confidence in a patient’s diagnosis; especially in cases of discriminating lung SqCC versus ADC, where a correct diagnosis is critical for therapeutic direction.
“The p40 monoclonal antibody shows equivalent sensitivity, but superior specificity compared to p63 and should become the standard IHC marker for lung cancer,” he adds.
The mouse monoclonal antibody has significantly less background and does not stain macrophages, according to the company.
The mouse monoclonal anti-p40 [BC28] was developed wholly by Biocare Medical through an intensive effort to identify an anti-p40 clone with superior staining performance in immunohistochemistry (IHC). p40 (M) [BC28] is available exclusively from the company and its worldwide network of distributors (patent pending).
p40 may have applications in cases where p63 has traditionally been used as an IHC marker. In recent studies, staining with rabbit polyclonal p40 was equivalent to p63 [4A4] in sensitivity for SqCC, but p40 exhibited markedly superior specificity due to staining in fewer cases of ADC compared to p63.1-3 p40 has also been reported in combination with TTF‑1 in a method to improve specificity for SqCC versus ADC, while preserving limited tissue specimens.3,4
Bishop JA, et al. Mod Pathol. 2012 Mar;25(3):405-15.
Nonaka D. Am J Surg Pathol. 2012 Jun;36(6):895-9.
Pelosi G, et al. J Thorac Oncol. 2012 Feb;7(2):281-90.
Brown AF, et al. Arch Pathol Lab Med. 2013 Jan 4.
[Source: Biocare Medical]